NCDEU Festschrift

Recently published articles about NCDEU Festschrift

JCP
NCDEU Festschrift

May 15, 2011

, ,
JCP
NCDEU Festschrift

May 15, 2011

Read the full article on the pharmalogic treatment of bipolar disorders with findings supported by clinical trials.
, ,
JCP
NCDEU Festschrift

May 15, 2011

JCP
NCDEU Festschrift

March 15, 2011

JCP
NCDEU Festschrift

March 15, 2011

JCP
NCDEU Festschrift

November 15, 2010

,

Recent JCP Articles on NCDEU Festschrift

JCP
Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder
Original Research

September 2, 2026

Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction.
, , , et al
PCC
Intrusive PTSD Symptoms and Elevated CRP in World Trade Center Responders
Original Research

September 1, 2026

Intrusive PTSD symptoms may contribute to systemic inflammation in WTC responders, thus targeting both PTSD symptoms and obesity/dyslipidemia may help mitigate risk for elevated systemic inflammation.
, , , et al
JCP
Pharmacotherapies for Co-Occurring Stimulant Use Disorder and ADHD
Meta-Analysis

August 31, 2026

Stimulant-based pharmacotherapies, particularly higher-dose methylphenidate and mixed amphetamine salts, were associated with superior outcomes for both stimulant-use indicators and ADHD symptoms.
, , , et al

Recent PCC Articles on NCDEU Festschrift

JCP
Electroconvulsive Therapy and All-Cause, Nonsuicide, and Suicide Mortality
Clinical and Practical Psychopharmacology

August 31, 2026

Evidence on the association of ECT with lower risk of short- and long-term all-cause mortality, nonsuicide mortality, and suicide mortality is reviewed.
Improved but Not Recovered: The Relapsing Course of Generalized Anxiety Disorder
news

August 28, 2026

GAD follows a chronic, relapsing course in which comorbidity reduces recovery odds and antidepressant discontinuation roughly triples relapse risk.
Safety Across Classic Psychedelics in GAD: What Three Investigational Programs Show So Far
news

August 28, 2026

Early safety data from lysergide, psilocybin, and deuterated DMT GAD trials show predominantly mild-to-moderate, session-concentrated adverse events across all three programs.

Featured NCDEU Festschrift Research

PCC
Managing 7-hydroxymitragynine Withdrawal
Case Report

August 27, 2026

A 49-year-old man taking “7-OH” experienced significant opioid withdrawal symptoms that resolved with high-dose buprenorphine-naloxone treatment.
,
JCP
Obstetric Risk Associated with Stimulant vs Nonstimulant Treatment
Original Research

August 26, 2026

Stimulant and nonstimulant use during pregnancy were both associated with increased risk for obstetric complications vs no medication.
,
JCP
ADHD Medication Safety in Pregnancy: Precise Estimates, Uncertain Causal Inference
Commentary

August 26, 2026

Comments on a recent study by Babinski and Tuan finding ADHD medication use predictive of adverse pregnancy outcomes.
JCP
NCDEU Festschrift

September 15, 2010

,
JCP
NCDEU Festschrift

September 15, 2010

JCP
NCDEU Festschrift

August 15, 2010

,
JCP
NCDEU Festschrift

July 15, 2010

JCP
NCDEU Festschrift

June 11, 2010

Read an article on the Pharmalogic treatment of anxiety disorders and findings supported by clinical trials.
,

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe